



2 September 2025

Our Ref: FOI 1334

Dear

**Freedom of Information Act 2000
Information in relation to Treatment of Cancers**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 6 August 2025.

A response to each of the questions raised has been provided by the Medicine, Unscheduled Care and Cancer Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Officer

Q1. How many patients were treated in total, regardless of diagnosis, with these medicines, in table 1, in the 3 months between 1st April 2025 to the end of June 2025, or latest 3-months for which data are available?

A1. Please see Table 1.

Table 1

Medicine	No. of Patients Treated
Abiraterone (Zytiga or generic abiraterone)	14
Apalutamide (Erleada)	5
Cabazitaxel (Jevtana or generic cabazitaxel)	5
Darolutamide (Nubeqa)	3
Enzalutamide (Xtandi)	61
Talazoparib (Talzenna)	Nil
Docetaxel	Nil
Relugolix (Orgovyx, Ryego)	Nil

Q2. How many patients were treated with these products, in table 2, specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st April 2025 to the end of June 2025, or latest 3-months for which data are available?

A2. Please see Table 2.

Table 2

Medicine	No. of Patients Treated
Docetaxel for prostate cancer	Nil
Olaparib (Lynparza) for prostate cancer	Nil
Talazoparib (Talzenna) for prostate cancer	Nil
Relugolix (Orgovyx) for prostate cancer	Nil

Q3. How many patients received their first cycle or first dose of the following products, in table 3, in the 3 months between 1st April 2025 to the end of June 2025, or latest 3-months for which data are available?

A3. Please see Table 3.

Table 3

Medicine	No. of Patients Treated
Abiraterone (Zytiga or generic abiraterone)	Nil
Apalutamide (Erleada)	Nil
Cabazitaxel (Jevtana or generic cabazitaxel)	2
Darolutamide (Nubeqa)	Nil
Enzalutamide (Xtandi)	10

Q4. How many patients were treated with the following combinations, in table 4, in the 3 months between 1st April 2025 to the end of June 2025, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle.

A4. Please see Table 4.

Table 4

Medicine	No. of Patients	No. of Patients Received Cycle 1 or Dose 1
Darolutamide (Nubeqa) + Docetaxel + ADT	Nil	Nil
Darolutamide (Nubeqa) + ADT	3	Nil
Olaparib (Lynparza) + Abiraterone	Nil	Nil

Q5. How many patients received the following products, for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st April 2025 to the end of June 2025, or latest 3-months for which data are available?

- **Abiraterone**
- **Enzalutamide**

A5. The information requested is not held on a central information system. To obtain this information would require a manual review of records.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

In accordance with the Freedom of Information Act 2000 this statement acts as a Refusal Notice in respect of question 5.